α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD

Create a personalized time and context curve of patient circulating α1-antitrypsin (AAT) levels and functions before hematopoietic stem cell transplantation and throughout progression into GVHD. PRIMARY ENDPOINT 1. Serum AAT levels and activity, before myeloablative preconditioning, as well as on days (-3),0,7,14,28 from HSCT and every 21 days thereafter. SECONDARY ENDPOINTS 1. Correlation between AAT patterns and: * Circulating immune cell activation profiles on day of ablation, 28 days from HSCT and once GVHD is diagnosed. * Patient survival * Liver function tests * GVHD grade: skin manifestations, weight, GI and liver histopathology * Graft-versus-leukemia effect